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Recurrent restenosis in saphenous vein graft. 
What is the next step?
Nawracająca restenoza w żylnym pomoście aortalno-wieńcowym
Paweł Tyczyński, Jacek Kądziela, Jerzy Pręgowski, Marcin Demkow, Adam Witkowski
Institute of Cardiology, Warsaw, Poland
The long-term outcome after percutaneous treatment of saphenous vein graft (SVG) is worse than of native corona-
ries. We present a patient with degenerated SVG, which had been treated with several interventions. Despite this, there 
was multiple recurrence of SVG-restenosis. A 76-year-old patient after implantation of a cardiac pacemaker, with arterial 
hypertension, atrial fibrillation, and chronic kidney disease, underwent coronary artery bypass grafting in 1993. Left internal 
mammary artery to left anterior descending artery, jump-SVG to marginal (Marg) and diagonal branches and SVG to right 
coronary artery (RCA) were inserted. Control angiography carried out 18 years later revealed occluded native coronary 
arteries and occluded SVG segment to Marg. Additionally, there was tight stenosis in RCA-SVG (Fig. 1A). Immediate 
intravascular ultrasound-guided percutaneous coronary intervention (PCI) of RCA-SVG was done with a 2.5 × 12 mm 
paclitaxel-eluting stent implantation and postdilatation. Seven months later, tight in-stent restenosis was diagnosed (Fig. 1B). 
After predilatation, a 2.5 × 18 mm zotarolimus-eluting stent was implanted. Subsequent two in-stent restenoses a few 
months later were treated twice with 3.0 × 25 mm paclitaxel-eluting balloons (Figs. 1C, D). The last in-stent restenosis 
(Fig. 1E) was treated with a 3.0 × 15 mm everolimus-eluting stent. There is no convincing proof of better long-term 
outcomes after SVG-PCI with drug-eluting stents (DES) compared to bare metal stents (BMS). DES significantly reduces 
the target vessel revascularisation (TVR) in SVG. However, there is no clear benefit on mortality and myocardial infarc-
tion. Histological examination of SVG-lesions shows a different pattern of restenosis compared to native coronaries, with 
enhanced inflammatory and thrombotic response. A Japanese restenosis registry in native coronaries indicated that if the 
original restenosis developed in a sirolimus-eluting stent (SES), it would more likely occur again after the next in-stent SES 
implantation. However, the need for TVR for second restenosis was rarer, if the original restenosis developed in BMS (and 
not in SES) and was subsequently treated with in-BMS SES implantation. Both first and second generation DES failed in 
our case. There have been no direct comparisons from randomised trials of different DES types for SVG. Chatani et al. 
(J Interv Cadiol, 2009; 22: 354–361) 
suggested that the only independent 
predictive factor of re-restenosis after 
SES-in-SES implantation in native 
coronaries was the reference diameter. 
In our case, we implanted two second 
generation DESs into a first genera-
tion DES. Additionally, two PCIs with 
drug-eluting balloons, postponed fur-
ther metal jacket insertion. After careful 
lesion preparation, implantation of the 
last (third) DES with larger diameter 
than the previous stents was possible. 
DESs have the advantage over BMSs 
in terms of SVG-TVR reduction, but in 
rare cases both DESs of first and second 
generation and drug-eluting balloon fail 
to prevent it. If a sixth restenosis were 
to occur, implantation of bioabsorbable 
vessel scaffolding or rotablation might 
be the treatment option.
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Figure 1. Recurrent restenosis in saphenous vein graft treated with drug-eluting 






A. Paclitaxel-eluting stent 
B. Zotarolimus-eluting stent
C. Paclitaxel-eluting balloon
D. Paclitaxel-eluting balloon
E. Everolimus-eluting stent
